Cellculture and transient protein expression are part of the expertise Magellan Biologics & Consulting offers to the scientific research community, therefore contributing to the progress of science biology and medicine for the benefit of patients.
We continuously develop our processes and products to propose the most advanced solutions in terms of yield of recombinant proteins, reproducibility and efficiency.
New Peer-Reviewed Paper in Antibodies Highlights Pfizer’s Outstanding Results with CHO 4Tx®
At the heart of this publication, entitled “A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology” and co-authored by Pfizer, Magellan Biologics, and
7 November 2025
